Anti-PD-1 antibody with or without capecitabine as maintenance therapy after first-line therapy of recurrent or metastatic nasopharyngeal carcinoma.

The NCI-9742 trial showed a nonsignificant trend for improved ORR in PD-L1-positive tumors, 56 whereas the JUPITER-02 and POLARIS-02 studies both demonstrated that patients benefited from immunotherapy, either as monotherapy or in combination with chemotherapy, regardless of PD-L1 expression. 15 , 57 Due to incomplete PD-L1 testing in our cohort, we could not assess its correlation with the outcomes.

also in 5,406 other papers